Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-02-05 DOI:10.1007/s12094-025-03847-8

Bilal Abu-Hussein, Amr Elrosasy, Haidy Samy, Ahmed Said Ali, Said Samir Alijla, Ahmad Naoras Bitar, Ibrahim Gamal

{"title":"Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials.","authors":"Bilal Abu-Hussein, Amr Elrosasy, Haidy Samy, Ahmed Said Ali, Said Samir Alijla, Ahmad Naoras Bitar, Ibrahim Gamal","doi":"10.1007/s12094-025-03847-8","DOIUrl":null,"url":null,"abstract":"Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide. According to the recent statistics by World Health Organization (WHO), it is the leading cause of death from cancer in women worldwide and it is the most frequently diagnosed cancer. This meta-analysis aims to systematically evaluate the efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.Method: We searched five databases; PubMed, Scopus, Science Direct, Web of Science, and Medline Plus. We included six studies. The applicable outcomes for meta-analysis about efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.Results: Six RCTs included in our meta-analysis found that Esketamine group had a statistically significant lower VAS score after 4 h, after 6 h, after 24 h, after 48 h; (MD = -1.54; 95% CI [-1.65, -1.42], P < 0.00001), (MD = -0.55; 95% CI [-0.66, -0.45], P < 0.00001), (MD = -0.75; 95% CI [-0.84, -0.66], P < 0.00001,), (MD = -0.26; 95% CI [-0.48, -0.03], P = 0.03) P < 0.00001), respectively.Conclusion: We conclude that S-ketamine is valuable for reducing pain and safe in patients undergoing modified radical mastectomy.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03847-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Breast cancer remains a leading cause of morbidity and mortality among women worldwide. According to the recent statistics by World Health Organization (WHO), it is the leading cause of death from cancer in women worldwide and it is the most frequently diagnosed cancer. This meta-analysis aims to systematically evaluate the efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.

Method: We searched five databases; PubMed, Scopus, Science Direct, Web of Science, and Medline Plus. We included six studies. The applicable outcomes for meta-analysis about efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.

Results: Six RCTs included in our meta-analysis found that Esketamine group had a statistically significant lower VAS score after 4 h, after 6 h, after 24 h, after 48 h; (MD = -1.54; 95% CI [-1.65, -1.42], P < 0.00001), (MD = -0.55; 95% CI [-0.66, -0.45], P < 0.00001), (MD = -0.75; 95% CI [-0.84, -0.66], P < 0.00001,), (MD = -0.26; 95% CI [-0.48, -0.03], P = 0.03) P < 0.00001), respectively.

Conclusion: We conclude that S-ketamine is valuable for reducing pain and safe in patients undergoing modified radical mastectomy.

查看原文本刊更多论文

背景：乳腺癌仍然是全球妇女发病和死亡的主要原因。根据世界卫生组织（WHO）最近的统计数据，乳腺癌是全球妇女死于癌症的主要原因，也是最常诊断出的癌症。本荟萃分析旨在系统评估S-氯胺酮对接受改良根治性乳房切除术患者的疗效和安全性：我们检索了五个数据库：PubMed、Scopus、Science Direct、Web of Science 和 Medline Plus。我们纳入了六项研究。对S-氯胺酮在改良根治性乳房切除术患者中的疗效和安全性进行荟萃分析：我们的荟萃分析纳入了 6 项研究，结果发现，4 h 后、6 h 后、24 h 后、48 h 后，Esketamine 组的 VAS 评分均显著降低，具有统计学意义；（MD = -1.54; 95% CI [-1.65, -1.42], P 结论：S-氯胺酮对改良根治性乳房切除术患者的疗效和安全性具有显著优势：我们得出的结论是，S-氯胺酮对接受改良根治性乳房切除术的患者有减轻疼痛的作用，并且是安全的。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.